A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
June 2021
in “
DOAJ (DOAJ: Directory of Open Access Journals)
”
TLDR JAK inhibitors show promise for treating alopecia areata but their effectiveness and safety are still debated.
The review explored the use of JAK inhibitors in treating alopecia areata (AA), a chronic immune-mediated hair loss condition. Despite AA often resolving spontaneously, the lack of approved treatments has led to reliance on off-label options with limited success. JAK inhibitors, which target the JAK-STAT signaling pathway to block T-cell mediated inflammation, have shown promise in reversing hair loss in AA patients. The review analyzed recent studies, including randomized controlled trials and other clinical reports, to assess the efficacy and safety of JAK inhibitors like ruxolitinib, tofacitinib, and baricitinib. However, the review highlighted the ongoing debate regarding their effectiveness and safety in managing AA.